Loading
Life sciences · Journal article
Pharmacognosy Magazine · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Kidney cancer constitutes a considerable worldwide health issue, significantly contributing to cancer-associated morbidity and mortality. Despite numerous advancements, existing treatment modalities for kidney cancer pose significant hurdles, including limited efficacy and elevated recurrence rates, necessitating safer and more effective alternative therapies. Purpose The current work was dedicated to studying the anti-cancer properties of piceatannol against kidney cancer cells. Materials and Methods The cytotoxic efficacy of piceatannol at varying dosages (5–100 µM) on renal cancer A498 cell viability was assessed utilizing the MTT test. The level of apoptotic incidence in control and piceatannol-treated A498 cells was assessed using a dual staining method. The caspase enzymes and the phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), and mammalian target of rapamycin (mTOR) protein levels in the untreated and piceatannol-treated A498 cells were evaluated using commercial kits. Results The results of the MTT assay suggested that piceatannol administration dose-dependently reduced A498 cell viability. The piceatannol administration increased the incidence of apoptosis in A498 cells, as evidenced by the dual-staining assay results. Furthermore, the piceatannol treatment enhanced the caspase-3, -8, and -9 levels and diminished the PI3K, AKT, and mTOR levels in the A498 cells. Conclusion The findings of this study suggested the anti-cancer effects of piceatannol against renal cell carcinoma. The development of piceatannol as a potential therapeutic option requires further validation. This study provides a foundation to understand the molecular mechanisms by which piceatannol affects A498 cells, warranting more studies into its role in renal cancer management.